CR20240245A - Uso del interferón como adyuvante en vacunas - Google Patents

Uso del interferón como adyuvante en vacunas

Info

Publication number
CR20240245A
CR20240245A CR20240245A CR20240245A CR20240245A CR 20240245 A CR20240245 A CR 20240245A CR 20240245 A CR20240245 A CR 20240245A CR 20240245 A CR20240245 A CR 20240245A CR 20240245 A CR20240245 A CR 20240245A
Authority
CR
Costa Rica
Prior art keywords
vaccines
interferon
adjuvant
fish
disclosed
Prior art date
Application number
CR20240245A
Other languages
English (en)
Inventor
Oyvind Haugland
Marit Rode
Linda Helena Hauge
Marius Andre De Feijter Karlsen
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CR20240245A publication Critical patent/CR20240245A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/38011—Tombusviridae
    • C12N2770/38022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se divulgan secuencias de interferón de salmón útiles como adyuvantes en vacunas para peces. También se divulgan vacunas para peces que utilizan dichas secuencias de interferón y métodos para la prevención de infecciones de peces que utilizan estas vacuna
CR20240245A 2021-12-20 2022-12-19 Uso del interferón como adyuvante en vacunas CR20240245A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163291585P 2021-12-20 2021-12-20
PCT/US2022/081916 WO2023122526A1 (en) 2021-12-20 2022-12-19 Use of interferon as an adjuvant in vaccines

Publications (1)

Publication Number Publication Date
CR20240245A true CR20240245A (es) 2024-09-13

Family

ID=85221940

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240245A CR20240245A (es) 2021-12-20 2022-12-19 Uso del interferón como adyuvante en vacunas

Country Status (12)

Country Link
US (1) US20250057946A1 (es)
EP (1) EP4452313A1 (es)
JP (1) JP2025501740A (es)
CN (1) CN118434443A (es)
AU (1) AU2022419971A1 (es)
CA (1) CA3243028A1 (es)
CL (1) CL2024001831A1 (es)
CO (1) CO2024007500A2 (es)
CR (1) CR20240245A (es)
DK (1) DK202470173A1 (es)
MX (1) MX2024007696A (es)
WO (1) WO2023122526A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4208157A1 (en) 2020-09-04 2023-07-12 Elanco Us Inc. Palatable formulations
DK202370610A1 (en) * 2022-12-13 2024-07-12 Zoetis Services Llc Methods of vaccine administration to salmonids
CN118956807B (zh) * 2024-10-17 2025-01-24 天津赛萌生物技术有限公司 一种组蛋白乙酰基转移酶突变体及其在生物大分子制备中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
CA2650730A1 (en) 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
WO2014118385A1 (en) * 2013-02-04 2014-08-07 University of Tromsø The use of dna sequences encoding an interferon as vaccine adjuvants
GB201415789D0 (en) 2014-09-05 2014-10-22 Touchlight Genetics Ltd Synthesis of DNA
US10456459B2 (en) 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
CN109844134B (zh) 2016-08-16 2023-05-05 塔驰莱特Ip有限公司 闭合线性dna的生产
GB201805683D0 (en) 2018-04-05 2018-05-23 Touchlight Ip Ltd Reprogramming vectors
GB202002068D0 (en) 2020-02-14 2020-04-01 Touchlight Ip Ltd DNA synthesis yield improvements

Also Published As

Publication number Publication date
JP2025501740A (ja) 2025-01-23
DK202470173A1 (en) 2024-07-12
EP4452313A1 (en) 2024-10-30
CN118434443A (zh) 2024-08-02
MX2024007696A (es) 2024-07-01
CA3243028A1 (en) 2025-04-07
CL2024001831A1 (es) 2024-10-18
US20250057946A1 (en) 2025-02-20
CO2024007500A2 (es) 2024-07-29
WO2023122526A1 (en) 2023-06-29
AU2022419971A1 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
CR20240245A (es) Uso del interferón como adyuvante en vacunas
WO2021226436A8 (en) Optimized nucleotide sequences encoding sars-cov-2 antigens
PH12021550484A1 (en) Immunological adjuvant and vaccine composition including sting agonist
MX2021015354A (es) Composiciones y metodos para administracion subcutanea de inmunoterapia de cancer.
MX2020008394A (es) Tratamiento que usa arn que codifica citoquinas.
CL2015002741A1 (es) Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos
EA201790507A1 (ru) Способы и композиции для усиления иммунных ответов
WO2014205199A3 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
AR081856A1 (es) Vacuna y metodos para reducir una infeccion por campylobacter
ZA202310663B (en) Immunogenic compositions to treat and prevent microbial infections
WO2020055932A3 (en) Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
MX2021007502A (es) Formulaciones y métodos de vacuna de norovirus.
BR112021017774A2 (pt) Dose baixa de citocina coadministrada com irgd para tratar câncer
EA201891287A1 (ru) Вакцинация с использованием альфа 3-домена mica/b для лечения рака
MX2022014984A (es) Atenuacion de virulencia bacteriana mediante atenuacion de transporte de folato bacteriano.
PH12020551413A1 (en) Use of direct-fed microbials in preventing and/or treating e. coli-based infections in animals
MX389088B (es) Métodos para tratar el vhc.
MX2022000263A (es) Nuevos antigenos y metodos contra el cancer.
MX2021015765A (es) Nuevos antigenos y metodos contra el cancer.
EP4324832A3 (en) Immunomodulatory compounds and use thereof for the treatment and/or prevention of infectious diseases
PH12017501853A1 (en) Bordetella pertussis immunogenic vaccine compositions
EA202100145A1 (ru) Применение гуанабенза
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
AR114683A1 (es) Polipéptidos inmunomoduladores e inmunoestimulantes para suministro de drogas
WO2021076906A8 (en) Tlr7/8 agonists to enhance immune responses in opioid using individuals